id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-338135-zwo7e7gy	Melis, Daniele	Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID‐19 pandemic	2020-05-30		.txt	text/plain	1517	71	45	Apremilast is an innovative small-molecule phosphodiesterase 4 inhibitor that has been approved for the treatment of moderate-to-severe plaque psoriasis in adult patients; it has a remarkable efficac y and safety profile and does not require particular screening or follow-up blood tests. 1 The main criticism seems to be its slower activity, in terms of the time required for improvement, with a low rate of Psoriasis Area and Severity Index (PASI) 75 achievement at week 16 in clinical trials: 33.1% of patients in ESTEEM1 and 28% of patients in ESTEEM2. Few real-world studies have investigated the profile of apremilast; [5] [6] [7] [8] [9] there have been no reports of efficacy after 8 weeks of treatment, which we valued as a PASI 50 achievement in 58% of patients and PASI 75 in 19%. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)	./cache/cord-338135-zwo7e7gy.txt	./txt/cord-338135-zwo7e7gy.txt